{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:38:41Z","timestamp":1783111121077,"version":"3.54.6"},"reference-count":50,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background\u2003Splanchnic vein thrombosis (SVT) is a common complication in patients with liver cirrhosis. The aim of this study was to evaluate the efficacy and safety of anticoagulant therapy for SVT in cirrhotic patients.<\/jats:p><jats:p>\n          Methods\u2003In this systematic review and meta-analysis, studies reporting on SVT recanalization and progression, recurrent venous thromboembolism (VTE), major bleeding, and overall mortality were searched in MEDLINE, EMBASE, and ClinicalTrial.gov up to December 2019. Pooled proportions and risk ratios (RRs) with corresponding 95% confidence intervals (CIs) were calculated.<\/jats:p><jats:p>\n          Results\u2003A total of 1,475 patients were included in 26 studies (23 observational and 3 randomized controlled trials). In patients receiving anticoagulant therapy, SVT recanalization occurred in 68% (95% CI, 62\u201374; 571\/842 patients; 22 studies), SVT progression in 6% (95% CI, 4\u20139; 25\/748 patients; 22 studies), recurrent VTE in 10% (95% CI, 4\u201322; 48\/399 patients; 7 studies), major bleeding in 6% (95% CI, 4\u201310; 58\/785 patients; 18 studies), and overall mortality in 9% (95% CI, 6\u201314; 68\/787 patients; 17 studies). Anticoagulant treatment was associated with higher SVT recanalization (RR 3.19; 95% CI, 1.42\u20137.17), lower thrombosis progression (RR 0.28; 95% CI, 0.15\u20130.52), major bleeding (RR 0.52; 95% CI, 0.28\u20130.97), and overall mortality (RR 0.42; 95% CI, 0.24\u20130.73) compared with no treatment.<\/jats:p><jats:p>\n          Conclusion\u2003Anticoagulant therapy seems to improve vein recanalization and to reduce SVT progression, major bleeding, and overall mortality in cirrhotic patients with SVT. The incidence of recurrent VTE during anticoagulation remains substantial.<\/jats:p>","DOI":"10.1055\/s-0040-1722192","type":"journal-article","created":{"date-parts":[[2021,2,2]],"date-time":"2021-02-02T03:28:36Z","timestamp":1612236516000},"page":"867-876","source":"Crossref","is-referenced-by-count":39,"title":["Anticoagulant Treatment for Splanchnic Vein Thrombosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis"],"prefix":"10.1055","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9729-3214","authenticated-orcid":false,"given":"Emanuele","family":"Valeriani","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral and Biotechnological Sciences, \u201cG. d'Annunzio\u201d University, Chieti, Italy"},{"name":"Diagnostic and Therapeutic Medicine Department, University Campus Bio-Medico of Rome, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5930-7304","authenticated-orcid":false,"given":"Marcello","family":"Di Nisio","sequence":"additional","affiliation":[{"name":"Department of Medicine and Ageing Sciences, \u201cG. d'Annunzio\u201d University, Chieti-Pescara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8922-8823","authenticated-orcid":false,"given":"Nicoletta","family":"Riva","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine and Surgery, University of Malta, Msida, Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Cohen","sequence":"additional","affiliation":[{"name":"National Hemophilia Center, Institute of Thrombosis and Hemostasis and the Amalia Biron Research Institute, Sheba Medical Center, Tel-Hashomer, Israel"},{"name":"Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ettore","family":"Porreca","sequence":"additional","affiliation":[{"name":"Department of Medical, Oral and Biotechnological Sciences, \u201cG. d'Annunzio\u201d University, Chieti, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Senzolo","sequence":"additional","affiliation":[{"name":"Multivisceral Transplant Unit, University Hospital of Padua, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Gottardi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Ente Ospedaliero Cantonale, Universit\u00e0 della Svizzera Italiana, Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Magaz","sequence":"additional","affiliation":[{"name":"Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Cl\u00ednic, IDIBAPS and CIBEREHD. University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan-Carlos","family":"Garcia-Pagan","sequence":"additional","affiliation":[{"name":"Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Cl\u00ednic, IDIBAPS and CIBEREHD. University of Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ageno","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, University of Insubria, Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"issue":"08","key":"ref1","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1055\/s-0038-1666861","article-title":"Concepts and controversies in haemostasis and thrombosis associated with liver disease: Proceedings of the 7th International Coagulation in Liver Disease Conference","volume":"118","author":"N M Intagliata","year":"2018","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.27546","article-title":"Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study","volume":"61","author":"F Nery","year":"2015","journal-title":"Hepatology"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1053\/j.gastro.2019.01.265","article-title":"Diagnosis, development, and treatment of portal vein thrombosis in patients with and without cirrhosis","volume":"156","author":"N M Intagliata","year":"2019","journal-title":"Gastroenterology"},{"issue":"06","key":"ref4","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1053\/j.gastro.2009.08.045","article-title":"An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis","volume":"137","author":"A Tripodi","year":"2009","journal-title":"Gastroenterology"},{"issue":"09","key":"ref5","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/liv.13087","article-title":"Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis","volume":"36","author":"V La Mura","year":"2016","journal-title":"Liver Int"},{"issue":"01","key":"ref7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/hep.1840220145","article-title":"The treatment of portal hypertension: a meta-analytic review","volume":"22","author":"G D'Amico","year":"1995","journal-title":"Hepatology"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis","volume":"153","author":"L Loffredo","year":"2017","journal-title":"Gastroenterology"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejim.2014.12.002","article-title":"Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies","volume":"26","author":"X Qi","year":"2015","journal-title":"Eur J Intern Med"},{"issue":"02","key":"ref10","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41395-018-0421-0","article-title":"Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis","volume":"114","author":"I Pettinari","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1148\/radiol.12112236","article-title":"Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis","volume":"265","author":"A Luca","year":"2012","journal-title":"Radiology"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ajg.2012.452","article-title":"De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes","volume":"108","author":"H Maruyama","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jhep.2015.07.040","article-title":"EASL clinical practice guidelines: vascular diseases of the liver","volume":"64","author":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu","year":"2016","journal-title":"J Hepatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/VHRM.S197732","article-title":"Splanchnic vein thrombosis: current perspectives","volume":"15","author":"E Valeriani","year":"2019","journal-title":"Vasc Health Risk Manag"},{"issue":"07","key":"ref15","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jth.14836","article-title":"Anticoagulant therapy for splanchnic vein thrombosis: ISTH SSC Subcommittee Control of Anticoagulation","volume":"18","author":"M Di Nisio","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"D Moher","year":"2009","journal-title":"PLoS Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"J A Sterne","year":"2016","journal-title":"BMJ"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"J P Higgins","year":"2003","journal-title":"BMJ"},{"issue":"09","key":"ref21","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2015.3184","article-title":"Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry","volume":"175","author":"W Ageno","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"25","key":"ref22","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood-2014-07-551515","article-title":"How I treat splanchnic vein thrombosis","volume":"124","author":"W Ageno","year":"2014","journal-title":"Blood"},{"key":"ref23","volume-title":"R: A language and environment for statistical computing","author":"R Core Team","year":"2019"},{"issue":"04","key":"ref24","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2009.06.009","article-title":"Portal vein thrombosis: a predictable milestone in cirrhosis?","volume":"51","author":"J C Garcia-Pagan","year":"2009","journal-title":"J Hepatol"},{"issue":"27","key":"ref25","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.4254\/wjh.v7.i27.2774","article-title":"Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis","volume":"7","author":"J G Stine","year":"2015","journal-title":"World J Hepatol"},{"issue":"09","key":"ref26","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1097\/00007890-200005150-00023","article-title":"Portal vein thrombosis in adults undergoing liver transplantation: risk factors, screening, management, and outcome","volume":"69","author":"M A Yerdel","year":"2000","journal-title":"Transplantation"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.3748\/wjg.v20.i10.2555","article-title":"Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis","volume":"20","author":"M Bolognesi","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"08","key":"ref28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41424-018-0043-2","article-title":"Long-term outcome of splanchnic vein thrombosis in cirrhosis","volume":"9","author":"M Senzolo","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1478-3231.2012.02785.x","article-title":"Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis","volume":"32","author":"M Senzolo","year":"2012","journal-title":"Liver Int"},{"issue":"08","key":"ref30","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1097\/MEG.0000000000000351","article-title":"Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B","volume":"27","author":"S B Cui","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"03","key":"ref31","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1148\/radiol.2015150369","article-title":"Is post-TIPS anticoagulation therapy necessary in patients with cirrhosis and portal vein thrombosis? A randomized controlled trial","volume":"279","author":"Z Wang","year":"2016","journal-title":"Radiology"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.vph.2018.05.002","article-title":"Randomized controlled trial of rivaroxaban versus warfarin in the management of acute non-neoplastic portal vein thrombosis","volume":"113","author":"A S Hanafy","year":"2019","journal-title":"Vascul Pharmacol"},{"issue":"12","key":"ref33","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/MEG.0b013e328357d5d4","article-title":"Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis","volume":"24","author":"L Amitrano","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"10","key":"ref34","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.gastrohep.2018.06.005","article-title":"Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis","volume":"41","author":"T Artaza","year":"2018","journal-title":"Gastroenterol Hepatol"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.jvir.2013.08.018","article-title":"Portal vein thrombosis after partial splenic embolization in liver cirrhosis: efficacy of anticoagulation and long-term follow-up","volume":"24","author":"M Cai","year":"2013","journal-title":"J Vasc Interv Radiol"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/hep.27783","article-title":"Impact of anticoagulation on upper-gastrointestinal bleeding in cirrhosis. A retrospective multicenter study","volume":"62","author":"F Cerini","year":"2015","journal-title":"Hepatology"},{"issue":"01","key":"ref37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MEG.0000000000000482","article-title":"Efficacy and safety of anticoagulation in more advanced portal vein thrombosis in patients with liver cirrhosis","volume":"28","author":"H Chen","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"04","key":"ref38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3350\/cmh.2014.20.4.384","article-title":"Safety, efficacy, and response predictors of anticoagulation for the treatment of nonmalignant portal-vein thrombosis in patients with cirrhosis: a propensity score matching analysis","volume":"20","author":"J W Chung","year":"2014","journal-title":"Clin Mol Hepatol"},{"issue":"05","key":"ref39","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/liv.13285","article-title":"Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis","volume":"37","author":"A De Gottardi","year":"2017","journal-title":"Liver Int"},{"issue":"07","key":"ref40","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"M G Delgado","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"05","key":"ref41","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gut.2004.042796","article-title":"Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation","volume":"54","author":"C Francoz","year":"2005","journal-title":"Gut"},{"issue":"11","key":"ref42","first-page":"716","article-title":"Prevalence and outcome of portal thrombosis in a cohort of cirrhotic patients undergoing liver transplantation","volume":"108","author":"M Hern\u00e1ndez Conde","year":"2016","journal-title":"Rev Esp Enferm Dig"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2018.01.032","article-title":"Low-molecular-weight heparin treatment for portal vein thrombosis in liver cirrhosis: efficacy and the risk of hemorrhagic complications","volume":"163","author":"J Kwon","year":"2018","journal-title":"Thromb Res"},{"issue":"07","key":"ref44","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.cgh.2017.10.016","article-title":"Harmful and beneficial effects of anticoagulants in patients with cirrhosis and portal vein thrombosis","volume":"16","author":"V La Mura","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis","volume":"48","author":"Y Nagaoki","year":"2018","journal-title":"Hepatol Res"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1111\/jth.12930","article-title":"Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study","volume":"13","author":"N Riva","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MEG.0000000000001237","article-title":"A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis","volume":"31","author":"K I Rodriguez-Castro","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"01","key":"ref48","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.transproceed.2018.07.014","article-title":"Utility of oral anticoagulants as prophylaxis of recurrent portal thrombosis after liver transplantation","volume":"51","author":"R Sanchez-Oca\u00f1a","year":"2019","journal-title":"Transplant Proc"},{"issue":"06","key":"ref49","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1007\/s10620-012-2548-y","article-title":"Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation","volume":"58","author":"K T Werner","year":"2013","journal-title":"Dig Dis Sci"},{"issue":"05","key":"ref50","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5152\/tjg.2015.0063","article-title":"The incidence and risk factors of portal vein system thrombosis after splenectomy and pericardial devascularization","volume":"26","author":"S Wu","year":"2015","journal-title":"Turk J Gastroenterol"},{"issue":"45","key":"ref51","doi-asserted-by":"crossref","first-page":"e8498","DOI":"10.1097\/MD.0000000000008498","article-title":"Portal vein thrombosis before and after transjugular intrahepatic portosystemic shunt placement: an observational study (STROBE compliant)","volume":"96","author":"Y M Wan","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1076029616689593","article-title":"Portal vein thrombosis in patients with cirrhosis undergoing elective transjugular intrahepatic portosystemic shunt: risk factors, warfarin efficacy, and clinical outcomes","volume":"24","author":"W Yue-Meng","year":"2018","journal-title":"Clin Appl Thromb Hemost"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1722192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,27]],"date-time":"2021-06-27T22:32:01Z","timestamp":1624833121000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1722192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":50,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2021,6,27]]},"published-print":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1722192","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}